Urology · Houston, TX
NPI
1225265168
Since 2009
Specialty
Urology
Code 208800000X
Group practices
1
Medicare group memberships
Hospitals
5
Hospital affiliations
6560 Fannin St Ste 1440
Houston, TX, 77030
Phone (713) 790-9700
Groups this clinician bills Medicare through
Medicare paid, 2024
$547K
14,647 services
Medicare patients, 2024
1,279
Average age 74
Drug cost, 2024
$1.5M
6,070 prescriptions
Company payments, 2025
$11K
From 25 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by David W Goldfarb was code Q9967 (low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml), 1,800 times for 16 patients. In total David W Goldfarb billed 14,647 services in 110 codes, and Medicare paid $547K.
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2019-06-04.
| Code | Setting | Services | Patients | Paid per service | Medicare paid |
|---|
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 1,800 | 16 | $0.10 | $184 |
| 99214 Office E&M - Established | Office | 1,436 | 933 | $90.12 | $129K |
| 99490 Chronic, Principal, and Transitional Care Management | Office | 1,240 | 190 | $46.72 | $58K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 1,109 | 828 | $12.15 | $13K |
| 36415 Venipuncture Blood Collection | Office | 837 | 636 | $8.38 | $7,010 |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 798 | 18 | $45.40 | $36K |
| 81003 Clinical Chemistry | Office | 737 | 521 | $2.19 | $1,617 |
| 51798 Ultrasound - Nonspecific | Office | 403 | 274 | $8.25 | $3,326 |
| 99439 Chronic, Principal, and Transitional Care Management | Office | 277 | 120 | $37.80 | $10K |
| 99443 Telephone Services | Office | 205 | 166 | $91.61 | $19K |
| 51741 Test - Miscellaneous | Office | 197 | 179 | $5.76 | $1,134 |
| 51728 Other Organ Systems | Office | 162 | 160 | $282.67 | $46K |
| 51797 Other Organ Systems | Office | 160 | 158 | $148.35 | $24K |
| 51784 Neurologic | Office | 155 | 117 | $32.96 | $5,109 |
| 99204 Office E&M - New | Office | 150 | 150 | $119.66 | $18K |
By year: 2022 $448K for 6,740 services; 2023 $506K for 8,249 services; 2024 $547K for 14,647 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 36415 Venipuncture Blood Collection | 837 | 636 | $8.38 | $7,010 |
| 81003 Clinical Chemistry | 737 | 521 | $2.19 | $1,617 |
Medicare prescription drug claims, 2024
In 2024, the drug David W Goldfarb prescribed most often to Medicare patients was Tamsulosin Hcl, with 1,163 prescriptions and refills. In total David W Goldfarb wrote 6,070 Medicare prescriptions that cost $1.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Tamsulosin Hcl Generic | 1,163 | 3,222 | 403 | $23K |
| Gemtesa Vibegron | 629 | 834 | 139 | $393K |
| Alfuzosin Hcl Er Alfuzosin Hcl | 506 | 1,368 | 171 | $15K |
| Myrbetriq Mirabegron | 485 | 759 | 117 | $334K |
| Testosterone Cypionate Generic | 442 | 538 | 98 | $17K |
| Solifenacin Succinate Generic | 399 | 997 | 150 | $19K |
| Finasteride Generic | 322 | 937 | 118 | $6,109 |
| Sulfamethoxazole-Trimethoprim Sulfamethoxazole/Trimethoprim | 263 | 271 | 192 | $1,029 |
| Xyosted Testosterone Enanthate | 159 | 178 | 27 | $106K |
| Anastrozole Generic | 159 | 410 | 45 | $981 |
| Ciprofloxacin Hcl Generic | 156 | 162 | 124 | $1,081 |
| Nitrofurantoin Mono-Macro Nitrofurantoin Monohyd/M-Cryst | 89 | 115 | 70 | $2,316 |
| Nitrofurantoin Nitrofurantoin Macrocrystal | 85 | 210 | 47 | $4,728 |
| Potassium Citrate Er Potassium Citrate | 80 | 194 | 29 | $11K |
| Oxybutynin Chloride Er Oxybutynin Chloride | 80 | 222 | 32 | $1,965 |
Brand drugs: - claims; generic drugs: 4,674 claims; opioid claims: 59.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid David W Goldfarb $11K ($11K in general payments such as food, travel and fees) from 25 companies. The largest payer was HMU Consumables, LLC with $5,143.
| Company | Payments | Amount |
|---|---|---|
| HMU Consumables, LLC | 2 | $5,143 |
| Biotissue Holdings Inc. | 85 | $3,274 |
| Boston Scientific Corporation BSX | 16 | $399 |
| Sumitomo Pharma America, Inc. 4506.T | 48 | $298 |
| Procept Biorobotics Corporation PRCT | 7 | $276 |
| Astellas Pharma US Inc 4503.T | 4 | $169 |
| Abbvie Inc. ABBV | 7 | $161 |
| Pfizer Inc. PFE | 3 | $91.3 |
| Endo USA, Inc. | 4 | $83.79 |
| Accord Healthcare, Inc. | 4 | $82.25 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.